Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 60,677 shares of Urogen Pharma stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $47.05, for a total value of $2,854,852.85. Following the sale, the insider directly owned 59,086 shares of the company's stock, valued at approximately $2,779,996.30. This represents a 50.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Mark Schoenberg also recently made the following trade(s):
- On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $40.00, for a total value of $400,000.00.
- On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total value of $350,100.00.
- On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The stock was sold at an average price of $27.30, for a total value of $142,560.60.
Urogen Pharma Stock Down 1.5%
Urogen Pharma stock opened at $46.16 on Tuesday. Urogen Pharma has a 52 week low of $15.86 and a 52 week high of $50.81. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -23.31 and a beta of 1.57. The stock has a 50-day moving average price of $40.82 and a 200 day moving average price of $29.32.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. Research analysts anticipate that Urogen Pharma will post -0.2 EPS for the current fiscal year.
Institutional Investors Weigh In On Urogen Pharma
A number of hedge funds and other institutional investors have recently made changes to their positions in URGN. California State Teachers Retirement System increased its holdings in shares of Urogen Pharma by 4,168.7% during the 2nd quarter. California State Teachers Retirement System now owns 1,654,123 shares of the company's stock valued at $60,872,000 after purchasing an additional 1,615,373 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Urogen Pharma by 15.1% during the second quarter. Wellington Management Group LLP now owns 115,362 shares of the company's stock worth $4,245,000 after buying an additional 15,147 shares in the last quarter. Palo Alto Investors LP acquired a new stake in Urogen Pharma during the second quarter valued at $901,600,000. Coastal Bridge Advisors LLC acquired a new stake in Urogen Pharma during the second quarter valued at $1,362,000. Finally, Jefferies Financial Group Inc. purchased a new position in Urogen Pharma in the second quarter valued at $80,947,000. Institutional investors and hedge funds own 91.29% of the company's stock.
Analyst Ratings Changes
URGN has been the topic of a number of research reports. UBS Group reiterated a "buy" rating on shares of Urogen Pharma in a research note on Thursday, July 9th. HC Wainwright boosted their target price on shares of Urogen Pharma from $45.00 to $75.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma in a report on Monday, May 11th. They issued a "buy" rating and a $43.00 price target on the stock. Oppenheimer increased their price target on Urogen Pharma from $40.00 to $50.00 and gave the stock an "outperform" rating in a research report on Thursday, July 16th. Finally, Guggenheim lifted their price objective on Urogen Pharma from $42.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $50.38.
View Our Latest Research Report on URGN
Urogen Pharma Company Profile
(
Get Free Report)
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
